Plain-English translation of NCT07378709 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying whether certain markers in your blood can help predict how well a standard liver cancer treatment called transarterial chemoembolization (TACE) is working for you. Right now, doctors rely mainly on imaging scans to see if the treatment worked, but blood tests might give doctors an earlier warning about whether the treatment is helping. This pilot study will collect blood samples from about 15 patients to explore this possibility.
Currently, doctors have to wait several weeks and use imaging scans to see if the treatment is working. A simple blood test that could predict treatment response earlier might help doctors make faster decisions about next steps and give patients valuable information sooner.
You likely qualify if…
You likely don't qualify if…
You would receive your standard liver cancer treatment (transarterial chemoembolization) as planned by your cancer team. In addition, you would donate blood samples before your first treatment and then again at follow-up visits when you come in for either another treatment or a routine CT scan. You would also have standard imaging scans (CT or MRI) about 4 to 8 weeks after treatment to check how well it worked — all of this is routine care. The study takes about 4 to 8 weeks from start to finish, with no extra visits required beyond your normal cancer appointments.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Serbia